A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

Phase 2 Terminated 1 enrolled American University of Beirut Medical Center Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an Open-label, single-arm, multicenter Phase II pilot study to assess the efficacy and safety of BMS-936558 with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma.

Timeline

Start: 2021-04-15
Primary completion: 2022-01-17
Completion: 2022-01-17

Outcome

Outcome not reported

Stopped (Business): “pharma company decision to withdraw the financial and IMP support”

Publications

Elias C, Zeidan YH, Bouferraa Y, Mukherji D, Temraz S, Charafeddine M, Al Darazi M, Shamseddine A. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer. 2022 Dec 12;22(1):1296. doi: 10.1186/s12885-022-10373-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	—	—